Navigation Links
Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
Date:11/4/2008

SAN DIEGO, Nov. 4 /PRNewswire/ -- Accumetrics, Inc. announces the appointment of William H. Dippel to the position of Executive Vice President of Operations and R&D. Mr. Dippel will oversee the Operations, Research and Product Development departments at Accumetrics.

"We are excited to have Bill join our team," said Timothy Still, President and Chief Executive Officer of Accumetrics. "Bill's 33 years of operations and R&D experience in the healthcare industry will be a tremendous asset to Accumetrics."

Prior to joining Accumetrics, Mr. Dippel was Vice President of Operations at Barrx Medical, Inc. Before joining Barrx, Mr. Dippel was Executive Vice President of HemoSense, Inc., responsible for R&D, Manufacturing, Engineering, Materials, and Facilities Management. He provided strong leadership introducing lean manufacturing resulting in improvements in gross margin, and later played a key role during the acquisition of HemoSense by Inverness Medical Innovations.

Prior to that position, Mr. Dippel was Vice President of Operations for Micro Therapeutics -- eV3. Earlier in his career, Mr. Dippel was with Conceptus, Inc. as Vice President of R&D and Operations, and PercuSurge (now a division of Medtronic, Inc.) as Vice President of Operations and held senior positions with Boehringer Mannheim GmbH (now Roche Diagnostics), Ciba Corning Diagnostic Corporation and Spectrum Technology, Inc.

Mr. Dippel holds a B.S. in Mechanical Engineering from the California State Polytechnic University, Pomona, California.

About Accumetrics

Accumetrics is committed to advancing medical understanding of the platelet function and enhancing the quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow(R) System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.

Contact:

Jules Abraham

Lippert/Heilshorn & Associates

212-838-3777

jabraham@lhai.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: